Price
CHART BY
Frequently asked questions
What is Alector's market capitalization?
The market capitalization of Alector is $225.55M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Alector?
Alector's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.092. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Alector's stock?
Currently, 6 analysts cover Alector's stock, with a consensus target price of $3.10. Analyst ratings provide insights into the stock's expected performance.
What is Alector's revenue over the trailing twelve months?
Over the trailing twelve months, Alector reported a revenue of $13.86M.
What is the EBITDA for Alector?
Alector's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$110.06M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Alector?
Alector has a free cash flow of -$158.39M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Alector have, and what sector and industry does it belong to?
Alector employs approximately 103 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Alector's shares?
The free float of Alector is 82.36M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $225.55M
- EPS (TTM)
- -$1.092
- Free Float
- 82.36M
- Revenue (TTM)
- $13.86M
- EBITDA (TTM)
- -$110.06M
- Free Cashflow (TTM)
- -$158.39M
Pricing
- 1D span
- $1.90$1.981
- 52W span
- $1.095$3.395
Analyst Ratings
The price target is $3.10 and the stock is covered by 6 analysts.
Buy
2
Hold
2
Sell
2
Information
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
- Employees
- 103
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ALEC
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet